Outcome following a short period of adalimumab dose escalation as rescue therapy in psoriatic patients
Fiche du document
2020
- handle: 10670/1.oymt9z
Cairn
Mots-clés
psoriasis Psoriasis Area and Severity Index (PASI) Dermatology Life Quality Index (DLQI) anti-TNFα adalimumabSujets proches
Therapy Treatments for diseases Medical treatment Therapy Treatment of diseases Life--PhilosophyCiter ce document
Federico Bardazzi et al., « Outcome following a short period of adalimumab dose escalation as rescue therapy in psoriatic patients », European Journal of Dermatology, ID : 10670/1.oymt9z
Métriques
Partage / Export
Résumé
Background: Advances in biologic treatments have led to a new therapeutic frontier for moderate-to-severe psoriasis. Nevertheless, the efficacy of anti-TNFα decreases with time, requiring adjustments to maintain valuable Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) responses. Objectives: To evaluate the efficacy and safety of adalimumab dose escalation (40 mg, subcutaneous, once a week for 24 weeks) in psoriatic adult patients with secondary loss of response (PASI ≥50 to ≤75 or PASI≥75 and DLQI ≥5). Materials and Methods: A multicentre, observational study involving different Italian third-level referral centres for psoriasis enrolled a total of 64 adult patients with moderate-to-severe psoriasis who were treated with adalimumab and experienced a secondary loss of response. Primary end-points were PASI> 75 or PASI ≥50 to ≤ 75 with DLQI ≤ 5, and the secondary end-point was the ability to maintain a therapeutic response, resuming adalimumab every other week. Results: At Week 16 and Week 24, 29/64 (45.3%) and 35/64 (54.6%) responded based on PASI, and mean DLQI was 4.9 and 4.09, respectively. At Week 36 and Week 48, 45.3% and 28.1% patients achieved the second end-point, respectively. No adverse events were recorded except for one patient with recurrent tonsillitis. Conclusion: Adalimumab escalation could be considered in cases with loss of response before switching to alternative biologic therapy.